But how different is ACU193 really?
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Retatrutide looks like the most powerful obesity agent yet, though side effects will need careful monitoring.
But investors aren’t buying it.
But it still has a long way to go with its islet cell therapies.